News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Sanofi (France) CEO Viehbacher on Stirring Innovation in the Era of R&D Cutbacks
January 17, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Chris Viehbacher has seen plenty of ideas come and go from people trying to shake up the pharma R&D model. No matter how much people have tried to fix things, it still takes a notorious amount of time, money, and risk to create new drugs.
Twitter
LinkedIn
Facebook
Email
Print
Europe
Sanofi
MORE ON THIS TOPIC
Regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
September 2, 2026
·
2 min read
·
Tristan Manalac
Insights
Fragile X at a turning point: Breaking through the clinical bottleneck
August 27, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Insights
Rewriting the rules of CMV prevention
August 20, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
7 biopharma M&A deals where layoffs followed
August 20, 2026
·
5 min read
·
Angela Gabriel